Mapp’s Ebola treatment comes through in a preclinical study

Damian Garde Tiny Mapp Biopharmaceutical's much-scrutinized Ebola treatment proved 100% effective in animal studies, the company said, stoking hopes that the investigational therapy ...

Novo Nordisk picks diabetes-ridden Mexico for first Ryzodeg launch

Tracy Staton Earlier this year, Novo Nordisk said it would target Mexico as its next market for an obesity-fighting formula of liraglutide, sold for diabetes as Victoza. Now, the company ...

Boehringer Ingelheim still being dogged by Ben Venue plant

Eric Palmer Boehringer Ingelheim is finding it difficult to get the stink of the troubled Ben Venue Bedford, OH, operations off its shoes. It closed the site last year and sold it last ...

Cabozantinib flops against prostate cancer, forcing big jobs cuts at Exelixis

John Carroll FierceBiotech News

Novartis’ LCZ696 kindles megablockbuster projections with impressive PhIII heart data

John Carroll Novartis told the world back in March that its experimental heart drug LCZ696 had delivered the goods early in a pivotal study, allowing for a quick wrap of the Phase III ...

Rumor mill churning as possible Pfizer/AstraZeneca Round 2 approaches

Carly Helfand Rumors about a potential new phase of the Pfizer/AstraZeneca takeover saga just won't go away, with all the talk giving the U.K. pharma's share price a lift this ...
Page 2 of 212
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS